Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890656 · ClinicalTrials.gov registry record · Phase 2
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00890656: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00890656 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00890656, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma. The safety of this therapy will also be studied.
Interventions
- DRUG Doxorubicin
- DRUG G-CSF
- DRUG Vincristine
- DRUG Cyclophosphamide (CTX)
- DRUG Decadron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-06 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890656
The ClinicalTrials.gov registry entry for NCT00890656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00890656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00890656 about?
NCT00890656 is a clinical study titled "Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage". The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma...
What is the current status of trial NCT00890656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00890656?
The interventions under investigation include: Doxorubicin (DRUG), G-CSF (DRUG), Vincristine (DRUG), Cyclophosphamide (CTX) (DRUG), Decadron (DRUG).
Who is sponsoring clinical trial NCT00890656?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.